Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Assessing orally bioavailable commercial silver nanoparticle product on human cytochrome P450 enzyme activity.

Munger MA, Hadlock G, Stoddard G, Slawson MH, Wilkins DG, Cox N, Rollins D.

Nanotoxicology. 2015 May;9(4):474-81. doi: 10.3109/17435390.2014.948092. Epub 2014 Aug 19.

PMID:
25137296
2.

Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.

Walzer M, Bekersky I, Blum RA, Tolbert D.

Pharmacotherapy. 2012 Apr;32(4):340-53. doi: 10.1002/j.1875-9114.2012.01028.x. Epub 2012 Mar 15.

PMID:
22422635
3.

In vivo human time-exposure study of orally dosed commercial silver nanoparticles.

Munger MA, Radwanski P, Hadlock GC, Stoddard G, Shaaban A, Falconer J, Grainger DW, Deering-Rice CE.

Nanomedicine. 2014 Jan;10(1):1-9. doi: 10.1016/j.nano.2013.06.010. Epub 2013 Jun 28.

4.

Assessment of orally dosed commercial silver nanoparticles on human ex vivo platelet aggregation.

Smock KJ, Schmidt RL, Hadlock G, Stoddard G, Grainger DW, Munger MA.

Nanotoxicology. 2014 May;8(3):328-33. doi: 10.3109/17435390.2013.788749. Epub 2013 May 2.

PMID:
23517080
5.

Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.

Bredberg E, Andersson TB, Frison L, Thuresson A, Johansson S, Eriksson-Lepkowska M, Larsson M, Eriksson UG.

Clin Pharmacokinet. 2003;42(8):765-77.

PMID:
12846597
6.

In vitro oxidative metabolism of cajaninstilbene Acid by human liver microsomes and hepatocytes: involvement of cytochrome p450 reaction phenotyping, inhibition, and induction studies.

Hua X, Peng X, Tan S, Li C, Wang W, Luo M, Fu Y, Zu Y, Smyth H.

J Agric Food Chem. 2014 Oct 29;62(43):10604-14. doi: 10.1021/jf501635a. Epub 2014 Oct 20.

PMID:
25272989
7.

Evaluation of drug-drug interaction potential of beraprost sodium mediated by P450 in vitro.

Fukazawa T, Yajima K, Miyamoto Y.

Yakugaku Zasshi. 2008 Oct;128(10):1459-65. Erratum in: Yakugaku Zasshi. 2010 Feb;130(2):277.

8.

In vivo effects of interleukin-10 on human cytochrome P450 activity.

Gorski JC, Hall SD, Becker P, Affrime MB, Cutler DL, Haehner-Daniels B.

Clin Pharmacol Ther. 2000 Jan;67(1):32-43.

PMID:
10668851
9.

Evaluation of the impact of Polygonum capitatum, a traditional Chinese herbal medicine, on rat hepatic cytochrome P450 enzymes by using a cocktail of probe drugs.

Zheng L, Lu Y, Cao X, Huang Y, Liu Y, Tang L, Liao SG, Wang AM, Li YJ, Lan YY, Wang YL.

J Ethnopharmacol. 2014 Dec 2;158 Pt A:276-82. doi: 10.1016/j.jep.2014.10.031. Epub 2014 Oct 29.

PMID:
25446640
10.

Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions.

Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T.

Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.

PMID:
10805063
11.

In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.

Derks M, Fowler S, Kuhlmann O.

Curr Med Res Opin. 2009 Apr;25(4):891-902. doi: 10.1185/03007990902790928 .

PMID:
19245299
12.

Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator.

Jornil J, Jensen KG, Larsen F, Linnet K.

Drug Metab Dispos. 2010 Mar;38(3):376-85. doi: 10.1124/dmd.109.030551. Epub 2009 Dec 10.

13.
14.

Interactions of herbs with cytochrome P450.

Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW.

Drug Metab Rev. 2003 Feb;35(1):35-98. Review.

PMID:
12635815
16.

Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity.

Pearce RE, McIntyre CJ, Madan A, Sanzgiri U, Draper AJ, Bullock PL, Cook DC, Burton LA, Latham J, Nevins C, Parkinson A.

Arch Biochem Biophys. 1996 Jul 15;331(2):145-69.

PMID:
8660694
17.
18.

Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes.

Liu Y, Zhang JW, Li W, Ma H, Sun J, Deng MC, Yang L.

Toxicol Sci. 2006 Jun;91(2):356-64. Epub 2006 Mar 17.

PMID:
16547074
19.

In vitro and in vivo evaluation of the effect of puerarin on hepatic cytochrome p450-mediated drug metabolism.

Kim SB, Yoon IS, Kim KS, Cho SJ, Kim YS, Cho HJ, Chung SJ, Chong S, Kim DD.

Planta Med. 2014 May;80(7):561-7. doi: 10.1055/s-0034-1368350. Epub 2014 Apr 7.

PMID:
24710899
20.

Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities.

Oganesian A, Shilling AD, Young-Sciame R, Tran J, Watanyar A, Azam F, Kao J, Leung L.

Psychopharmacol Bull. 2009;42(2):47-63.

PMID:
19629022

Supplemental Content

Support Center